Sivelestat sodium
|
|
|
- CAS-Nr.
- 201677-61-4
- Englisch Name:
- Sivelestat sodium
- Synonyma:
- Elaspol;Sivelestat sodium;Sivelestat(anhydrous);SIVELESTAT SODIUM HYDRATE;EI546 sodium tetrahydrate;ONO5046 sodium tetrahydrate;LY544349 sodium tetrahydrate;Sivelestat sodium Impurity A;SIVELESTAT SODIUM TETRAHYDRATE;Ono-EI-600 sodium tetrahydrate
- CBNumber:
- CB4679778
- Summenformel:
- C20H25N2NaO8S
- Molgewicht:
- 476.48
- MOL-Datei:
- 201677-61-4.mol
|
Sivelestat sodium Eigenschaften
- storage temp.
- Sealed in dry,Room Temperature
- Löslichkeit
- Soluble in DMSO (up to 20 mg/ml).
- Aggregatzustand
- White solid.
- Farbe
- White
- Stabilität:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months
- CAS Datenbank
- 201677-61-4(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Sivelestat sodium Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Sivelestat is an acyl enzyme inhibitor of neutrophil elastase, developed as an injectable
formulation for the treatment of acute lung injury associated with systemic inflammatory
response syndrome. A neutrophil predominant inflammation associated with excessive
release of human neutrophil elastase (HNE) from azurophilic granules is capable of
damaging both the lung parenchymal cells and the extracellular matrix allowing an alveolar
capillary barrier disruption. Sivelestat is a sulfonanilide-containing pivaloyloxy benzene
derivative prepared in a three step synthesis. This agent acts as a reversible and selective
inhibitor of HNE with an lG.0 value of 0.044 PM. Sivelestat has exhibited potent protective
effects against various causes of lung injuries in animal models. In an acid-induced acute
lung injury model in conscious hamster, administration of sivelestat for 48 h following HCI
instillation, dose-dependently reduced mortality and significantly improved the protein
levels in bronchoalveolar lavage fluids and pulmonary artery pressure. In a similar study,
the agent inhibited the endotoxin-induced acute lung dysfunctions (marked elevation of
pulmonary vascular permeability, leukocyte migration, hemorrhage and parenchymal
injury) in different animal species. Moreover, in a cardiopulmonary bypass model in dog,
sivelestat ameliorated the respiratory index and interstitial-intra-alveolar edema. Sivelestat
has a relatively poor bioavailability, due to an extensive first-pass metabolism and is easily
hydrolyzed in vitro to an inactive metabolite. In two animal species, the half-life time was
approximately 5-7 min. Clinical trials have shown that treatment with the agent improves
respiratory function and facilitates early removal of patients from mechanical ventilation.
However, in the last clinical study, conducted by Eli Lilly in patients with acute lung injury,
no difference in mortality and safety was seen between sivelestat and placebo.
Verwenden
Treatment of acute lung injury; acute respiratory distress syndrome (elastase inhibitor).
Sivelestat sodium Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Sivelestat sodium Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 143)Lieferanten
201677-61-4()Verwandte Suche:
- SIVELESTAT SODIUM HYDRATE
- SIVELESTAT SODIUM TETRAHYDRATE
- n-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-(s)-glycine monosodium salt tetrahydrate
- Sivelestat sodium
- N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-Glycine monosodium salt tetrahydrate
- Sivelestat(anhydrous)
- Glycine, N-[2-[[[4-(2,2-diMethyl-1-oxopropoxy)phenyl]sulfonyl]aMino]benzoyl]-, MonosodiuM salt, tetrahydrate
- sodium,2-[[2-[[4-(2,2-dimethylpropanoyloxy)phenyl]sulfonylamino]benzoyl]amino]acetate,tetrahydrate
- Sivelestat sodium Impurity A
- EI546 sodium tetrahydrate
- LY544349 sodium tetrahydrate
- ONO5046 sodium tetrahydrate
- LY 544349;ONO-5046;LY-544349;LY544349
- Sivelestat sodium hydrate (ONO-5046 sodium hydrate)
- Propanoic acid, 2,2-dimethyl-, 4-[[[2-[[(carboxymethyl)amino]carbonyl]phenyl]amino]sulfonyl]phenyl ester, sodium salt, hydrate (1:1:4)
- Elaspol
- Sodium 2-(2-(4-(pivaloyloxy)phenylsulfonamido)benzamido)acetate tetrahydrate
- Ono-EI-600 sodium tetrahydrate
- 201677-61-4
- C20H21N2O7SNa4H2O
- C20H21N2NaO7S
- C20H21N2NaO7S4H2O
- C20H29N2NaO11S
